Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches
Expert Opinion on Drug Discovery January 31, 2025 Aline Silva de Miranda, Eliana C B Toscano, Venugopal Reddy Venna et al. 2 citations
Understanding the multiple pathophysiological mechanisms involved in treatment-resistant depression (TRD) may improve treatment by enabling a more personalized approach. Esketamine has been approved for TRD, and novel drugs with rapid antidepressant actions, such as psilocybin and buprenorphine, are being investigated as potential therapies. Technological advances like omics approaches have expanded knowledge of the molecular and genetic underpinnings of TRD and could open new avenues for studying glial-mediated mechanisms, including their interactions with neurons, as therapeutic targets.